$0.22
0.00 (-1.86%)
Open$0.23
Previous Close$0.22
Day High$0.23
Day Low$0.21
52W High$0.86
52W Low$0.16
Volume—
Avg Volume408.8K
Market Cap10.60M
P/E Ratio—
EPS$-0.64
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+17,789.1% upside
Current
$0.22
$0.22
Target
$38.73
$38.73
$26.34
$38.73 avg
$46.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.08M | 955.9K |
| Net Income | -22,361 | -31,787 | -25,174 |
| Profit Margin | -2.2% | -2.9% | -2.6% |
| EBITDA | -38,355 | -35,389 | -33,870 |
| Free Cash Flow | -18,843 | -19,077 | -22,857 |
| Rev Growth | +0.6% | -3.8% | +4.7% |
| Debt/Equity | 0.84 | 0.93 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |